ABVC Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ABVC Nasdaq 8731 https://abvcpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABVC Biopharma Inc

ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials - Dec 5th, 2023 1:30 pm
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market - Nov 21st, 2023 1:30 pm
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M - Nov 16th, 2023 3:05 pm
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results - Nov 15th, 2023 2:00 pm
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million - Oct 26th, 2023 12:30 pm
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study - Oct 17th, 2023 12:30 pm
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD) - Oct 9th, 2023 12:30 pm
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study - Aug 23rd, 2023 12:30 pm
ABVC Executes Cooperation Agreement for Strategic Investments - Aug 17th, 2023 1:19 pm
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement - Aug 10th, 2023 12:30 pm
ABVC Corporate Update and CEO's Letter to Shareholders - Aug 7th, 2023 12:30 pm
ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration - Aug 3rd, 2023 1:20 pm
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales - Aug 1st, 2023 12:30 pm
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering - Jul 31st, 2023 1:30 pm
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering - Jul 27th, 2023 1:22 pm
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments - Jul 26th, 2023 12:30 pm
ABVC BioPharma Announces Reverse Stock Split - Jul 24th, 2023 4:30 pm
The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency - Jul 6th, 2023 12:30 pm
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth - Jun 26th, 2023 12:30 pm
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production - Jun 20th, 2023 12:30 pm